Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response

Karolinska Institutet93 enrolled

Overview

In this international collaboration study, the research group will analyze somatic mutations of hepatocellular carcinoma (HCC) developed after sustained virological response (SVR) in patients treated with hepatitis C (HCV) therapy

Method Paired liver tissue samples will be collected from the tumour sections and also from the adjacent non-tumour tissues, for comparison in each individual. The tissues have been collected as part of routine clinical work/other studies, by liver biopsies or at liver resection/liver transplantation. Data regarding the patient characteristic will be collected. Whole genome sequencing analyses are planned to be performed.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatocellular Carcinoma Hepatitis C

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with sustained virological response (SVR) after interferon (IFN)-containing or IFN-free treatment, and developed hepatocellular carcinoma (HCC) * Available liver biopsies from hepatocellular carcinoma and non-HCC tissue Exclusion Criteria: * Co-infection with chronic hepatitis B (HBsAg positive) or HIV infection. * Liver transplantation prior to treatment-start, leading to SVR. * Patients with diagnosed HCC prior to treatment-start, leading to SVR.

Locations (1)

Karolinska Institutet

Stockholm, Sweden

Outcomes

Primary Outcomes

Characterisation of genomic mutations of HCC, developed in HCV patients with SVR

Genetic characteristics of HCCs will be compared to non-HCC tissue

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.